A strategic alliance has been reached by Infuseon Therapeutics and OncoSynergy to establish proof of concept for the direct delivery of OncoSynergy's monoclonal pan-CD29 antibody OS2966 to the brain using Infuseon's Cleveland Multiport Catheter. The proof of concept will be used as a springboard to conduct a Phase I trial of the combined solutions for treating glioblastoma.
Infuseon enters glioblastoma treatment partnership with OncoSynergy
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.